MedTrace Logo

Chemoimmunotherapy and Radiation in Pancreatic Cancer

NCT01903083 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2018-02-01

No results posted yet for this study

Summary

The goal of this study is to evaluate the safety of combination treatment that includes chemotherapy, radiation therapy, and immunotherapy in patients with pancreatic cancer.

Conditions

  • Locally Advanced Malignant Neoplasm

Interventions

DRUG

Tadalafil

One 2.5 mg tablet is self-administered orally by the study participant on a once daily basis.

DRUG

Gemcitabine

Three doses of gemcitabine (1000 mg / m\^2)are given over a 21-day cycle. Patients may receive up to 4 cycles.

RADIATION

Radiation

Patients will receive 3 doses of radiation (8-10 Gy per fraction).

PROCEDURE

Pancreaticoduodenectomy

Surgical resection.

Sponsors & Collaborators

Principal Investigators

  • Todd Crocenzi, MD · Providence Health & Services

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01903083 on ClinicalTrials.gov